In the last three decades, although much progress for cancer diagnosis and treatment has been achieved, cancer is still the second leading cause of death in the United States after heart disease. Detecting early-stage cancer before metastasis and obtaining effective therapy against the cancer are currently main hurdles that need to be overcome. Meanwhile, the development of imaging modalities such as magnetic resonance imaging (MRI), computed tomography (CT), and positron emission tomography (PET) opens the new possibility to detect cancer at the early stage. With the advanced imaging modalities in nanomedicine using nano-sized particles (NPs), there suggests a new paradigm developing for early diagnosis and detection with effective therapy at the same time (theranosis). In my presentation, I will talk about the use of iron oxide-based NPs as a magnetic resonance (MR) contrast agent. In addition, I will explore the design of these NPs for optimized theranosis in the treatment of cancer.
Researchers should cite this work as follows:
Burton Morgan 121, Purdue University, West Lafayette, IN